![biaoTi](/_nuxt/img/biaoTi.0d1dc71.webp)
![biaoTi](/_nuxt/img/biaoTi.0d1dc71.webp)
Part 1
Part 2
Part 3
Part 5
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively. The global market for Kidney Fibrosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Report Scope This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Kidney Fibrosis Treatment by region & country, by Type, and by Application. The Kidney Fibrosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Treatment. Market Segmentation
Report Metric
Details
Report Title
Kidney Fibrosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Kidney Fibrosis Treatment Companies Covered
Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel), Genzyme Corporation(US)
Global Kidney Fibrosis Treatment Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Kidney Fibrosis Treatment Market, Segment by Type
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney Fibrosis Treatment Market, Segment by Application
Chronic Kidney Diseases
Kidney Cancer Treatment
Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends
Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Kidney Fibrosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Revenue of Kidney Fibrosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Revenue of Kidney Fibrosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion.
1 Market Overview
1.1 Kidney Fibrosis Treatment Product Introduction
1.2 Global Kidney Fibrosis Treatment Market Size Forecast
1.3 Kidney Fibrosis Treatment Market Trends & Drivers
1.3.1 Kidney Fibrosis Treatment Industry Trends
1.3.2 Kidney Fibrosis Treatment Market Drivers & Opportunity
1.3.3 Kidney Fibrosis Treatment Market Challenges
1.3.4 Kidney Fibrosis Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered2 Competitive Analysis by Company
2.1 Global Kidney Fibrosis Treatment Players Revenue Ranking (2023)
2.2 Global Kidney Fibrosis Treatment Revenue by Company (2019-2024)
2.3 Key Companies Kidney Fibrosis Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Kidney Fibrosis Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Kidney Fibrosis Treatment
2.6 Kidney Fibrosis Treatment Market Competitive Analysis
2.6.1 Kidney Fibrosis Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Kidney Fibrosis Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
3.1.2 Pirfenidone
3.1.3 Renin Inhibitors
3.1.4 Angiotensin II Receptor Blockers (ARBs)
3.1.5 Vasopeptidase Inhibitors
3.2 Global Kidney Fibrosis Treatment Sales Value by Type
3.2.1 Global Kidney Fibrosis Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Kidney Fibrosis Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Kidney Fibrosis Treatment Sales Value, by Type (%) (2019-2030)4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Chronic Kidney Diseases
4.1.2 Kidney Cancer Treatment
4.1.3 Others
4.2 Global Kidney Fibrosis Treatment Sales Value by Application
4.2.1 Global Kidney Fibrosis Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Kidney Fibrosis Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Kidney Fibrosis Treatment Sales Value, by Application (%) (2019-2030)5 Segmentation by Region
5.1 Global Kidney Fibrosis Treatment Sales Value by Region
5.1.1 Global Kidney Fibrosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024)
5.1.3 Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030)
5.1.4 Global Kidney Fibrosis Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Kidney Fibrosis Treatment Sales Value, 2019-2030
5.2.2 North America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Kidney Fibrosis Treatment Sales Value, 2019-2030
5.3.2 Europe Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Kidney Fibrosis Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Kidney Fibrosis Treatment Sales Value, 2019-2030
5.5.2 South America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Kidney Fibrosis Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 20306 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Kidney Fibrosis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Kidney Fibrosis Treatment Sales Value
6.3 United States
6.3.1 United States Kidney Fibrosis Treatment Sales Value, 2019-2030
6.3.2 United States Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Kidney Fibrosis Treatment Sales Value, 2019-2030
6.4.2 Europe Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Kidney Fibrosis Treatment Sales Value, 2019-2030
6.5.2 China Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Kidney Fibrosis Treatment Sales Value, 2019-2030
6.6.2 Japan Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Kidney Fibrosis Treatment Sales Value, 2019-2030
6.7.2 South Korea Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Kidney Fibrosis Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Kidney Fibrosis Treatment Sales Value, 2019-2030
6.9.2 India Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 20307 Company Profiles
7.1 Merck and Co(US)
7.1.1 Merck and Co(US) Profile
7.1.2 Merck and Co(US) Main Business
7.1.3 Merck and Co(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.1.4 Merck and Co(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Merck and Co(US) Recent Developments
7.2 Pfizer Inc(US)
7.2.1 Pfizer Inc(US) Profile
7.2.2 Pfizer Inc(US) Main Business
7.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.2.4 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Pfizer Inc(US) Recent Developments
7.3 F. Hoffman-La Roche(Switzerland)
7.3.1 F. Hoffman-La Roche(Switzerland) Profile
7.3.2 F. Hoffman-La Roche(Switzerland) Main Business
7.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products, Services and Solutions
7.3.4 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 InterMune Inc(US) Recent Developments
7.4 InterMune Inc(US)
7.4.1 InterMune Inc(US) Profile
7.4.2 InterMune Inc(US) Main Business
7.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.4.4 InterMune Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 InterMune Inc(US) Recent Developments
7.5 Galectin Therapeutics(US)
7.5.1 Galectin Therapeutics(US) Profile
7.5.2 Galectin Therapeutics(US) Main Business
7.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.5.4 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Galectin Therapeutics(US) Recent Developments
7.6 La Jolla Pharmaceutical Company(US)
7.6.1 La Jolla Pharmaceutical Company(US) Profile
7.6.2 La Jolla Pharmaceutical Company(US) Main Business
7.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.6.4 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 La Jolla Pharmaceutical Company(US) Recent Developments
7.7 ProMetic Life-Sciences Inc(Canada)
7.7.1 ProMetic Life-Sciences Inc(Canada) Profile
7.7.2 ProMetic Life-Sciences Inc(Canada) Main Business
7.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products, Services and Solutions
7.7.4 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 ProMetic Life-Sciences Inc(Canada) Recent Developments
7.8 BioLine Rx(Israel)
7.8.1 BioLine Rx(Israel) Profile
7.8.2 BioLine Rx(Israel) Main Business
7.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Products, Services and Solutions
7.8.4 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 BioLine Rx(Israel) Recent Developments
7.9 Genzyme Corporation(US)
7.9.1 Genzyme Corporation(US) Profile
7.9.2 Genzyme Corporation(US) Main Business
7.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Products, Services and Solutions
7.9.4 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Genzyme Corporation(US) Recent Developments8 Industry Chain Analysis
8.1 Kidney Fibrosis Treatment Industrial Chain
8.2 Kidney Fibrosis Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Kidney Fibrosis Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Kidney Fibrosis Treatment Distributors9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Kidney Fibrosis Treatment Market Trends Table 2. Kidney Fibrosis Treatment Market Drivers & Opportunity Table 3. Kidney Fibrosis Treatment Market Challenges Table 4. Kidney Fibrosis Treatment Market Restraints Table 5. Global Kidney Fibrosis Treatment Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Kidney Fibrosis Treatment Revenue Market Share by Company (2019-2024) Table 7. Key Companies Kidney Fibrosis Treatment Manufacturing Base Distribution and Headquarters Table 8. Key Companies Kidney Fibrosis Treatment Product Type Table 9. Key Companies Time to Begin Mass Production of Kidney Fibrosis Treatment Table 10. Global Kidney Fibrosis Treatment Companies Market Concentration Ratio (CR5 and HHI) Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2023) Table 12. Mergers & Acquisitions, Expansion Plans Table 13. Global Kidney Fibrosis Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 14. Global Kidney Fibrosis Treatment Sales Value by Type (2019-2024) & (US$ Million) Table 15. Global Kidney Fibrosis Treatment Sales Value by Type (2025-2030) & (US$ Million) Table 16. Global Kidney Fibrosis Treatment Sales Market Share in Value by Type (2019-2024) & (%) Table 17. Global Kidney Fibrosis Treatment Sales Market Share in Value by Type (2025-2030) & (%) Table 18. Global Kidney Fibrosis Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 19. Global Kidney Fibrosis Treatment Sales Value by Application (2019-2024) & (US$ Million) Table 20. Global Kidney Fibrosis Treatment Sales Value by Application (2025-2030) & (US$ Million) Table 21. Global Kidney Fibrosis Treatment Sales Market Share in Value by Application (2019-2024) & (%) Table 22. Global Kidney Fibrosis Treatment Sales Market Share in Value by Application (2025-2030) & (%) Table 23. Global Kidney Fibrosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 24. Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024) & (US$ Million) Table 25. Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030) & (US$ Million) Table 26. Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024) & (%) Table 27. Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030) & (%) Table 28. Key Countries/Regions Kidney Fibrosis Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 29. Key Countries/Regions Kidney Fibrosis Treatment Sales Value, (2019-2024) & (US$ Million) Table 30. Key Countries/Regions Kidney Fibrosis Treatment Sales Value, (2025-2030) & (US$ Million) Table 31. Merck and Co(US) Basic Information List Table 32. Merck and Co(US) Description and Business Overview Table 33. Merck and Co(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 34. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Merck and Co(US) (2019-2024) Table 35. Merck and Co(US) Recent Developments Table 36. Pfizer Inc(US) Basic Information List Table 37. Pfizer Inc(US) Description and Business Overview Table 38. Pfizer Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 39. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Pfizer Inc(US) (2019-2024) Table 40. Pfizer Inc(US) Recent Developments Table 41. F. Hoffman-La Roche(Switzerland) Basic Information List Table 42. F. Hoffman-La Roche(Switzerland) Description and Business Overview Table 43. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products, Services and Solutions Table 44. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of F. Hoffman-La Roche(Switzerland) (2019-2024) Table 45. F. Hoffman-La Roche(Switzerland) Recent Developments Table 46. InterMune Inc(US) Basic Information List Table 47. InterMune Inc(US) Description and Business Overview Table 48. InterMune Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 49. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of InterMune Inc(US) (2019-2024) Table 50. InterMune Inc(US) Recent Developments Table 51. Galectin Therapeutics(US) Basic Information List Table 52. Galectin Therapeutics(US) Description and Business Overview Table 53. Galectin Therapeutics(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 54. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Galectin Therapeutics(US) (2019-2024) Table 55. Galectin Therapeutics(US) Recent Developments Table 56. La Jolla Pharmaceutical Company(US) Basic Information List Table 57. La Jolla Pharmaceutical Company(US) Description and Business Overview Table 58. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 59. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of La Jolla Pharmaceutical Company(US) (2019-2024) Table 60. La Jolla Pharmaceutical Company(US) Recent Developments Table 61. ProMetic Life-Sciences Inc(Canada) Basic Information List Table 62. ProMetic Life-Sciences Inc(Canada) Description and Business Overview Table 63. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products, Services and Solutions Table 64. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of ProMetic Life-Sciences Inc(Canada) (2019-2024) Table 65. ProMetic Life-Sciences Inc(Canada) Recent Developments Table 66. BioLine Rx(Israel) Basic Information List Table 67. BioLine Rx(Israel) Description and Business Overview Table 68. BioLine Rx(Israel) Kidney Fibrosis Treatment Products, Services and Solutions Table 69. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of BioLine Rx(Israel) (2019-2024) Table 70. BioLine Rx(Israel) Recent Developments Table 71. Genzyme Corporation(US) Basic Information List Table 72. Genzyme Corporation(US) Description and Business Overview Table 73. Genzyme Corporation(US) Kidney Fibrosis Treatment Products, Services and Solutions Table 74. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Genzyme Corporation(US) (2019-2024) Table 75. Genzyme Corporation(US) Recent Developments Table 76. Key Raw Materials Lists Table 77. Raw Materials Key Suppliers Lists Table 78. Kidney Fibrosis Treatment Downstream Customers Table 79. Kidney Fibrosis Treatment Distributors List Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources Table 83. Business Unit and Senior & Team Lead Analysts List of Figures Figure 1. Kidney Fibrosis Treatment Product Picture Figure 2. Global Kidney Fibrosis Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 4. Kidney Fibrosis Treatment Report Years Considered Figure 5. Global Kidney Fibrosis Treatment Players Revenue Ranking (2023) & (US$ Million) Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Kidney Fibrosis Treatment Revenue in 2023 Figure 7. Kidney Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 8. Angiotensin Converting Enzyme (ACE) Inhibitors Picture Figure 9. Pirfenidone Picture Figure 10. Renin Inhibitors Picture Figure 11. Angiotensin II Receptor Blockers (ARBs) Picture Figure 12. Vasopeptidase Inhibitors Picture Figure 13. Global Kidney Fibrosis Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 14. Global Kidney Fibrosis Treatment Sales Value Market Share by Type, 2023 & 2030 Figure 15. Product Picture of Chronic Kidney Diseases Figure 16. Product Picture of Kidney Cancer Treatment Figure 17. Product Picture of Others Figure 18. Global Kidney Fibrosis Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 19. Global Kidney Fibrosis Treatment Sales Value Market Share by Application, 2023 & 2030 Figure 20. North America Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 21. North America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030 Figure 22. Europe Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 23. Europe Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030 Figure 24. Asia Pacific Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 25. Asia Pacific Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030 Figure 26. South America Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 27. South America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030 Figure 28. Middle East & Africa Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million) Figure 29. Middle East & Africa Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030 Figure 30. Key Countries/Regions Kidney Fibrosis Treatment Sales Value (%), (2019-2030) Figure 31. United States Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 32. United States Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 33. United States Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 34. Europe Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 35. Europe Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 36. Europe Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 37. China Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 38. China Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 39. China Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 40. Japan Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 41. Japan Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 42. Japan Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 43. South Korea Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 44. South Korea Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 45. South Korea Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 46. Southeast Asia Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 47. Southeast Asia Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 48. Southeast Asia Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 49. India Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million) Figure 50. India Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030 Figure 51. India Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030 Figure 52. Kidney Fibrosis Treatment Industrial Chain Figure 53. Kidney Fibrosis Treatment Manufacturing Cost Structure Figure 54. Channels of Distribution (Direct Sales, and Distribution) Figure 55. Bottom-up and Top-down Approaches for This Report Figure 56. Data Triangulation
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively. The global market for Kidney Fibrosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Report Scope This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Kidney Fibrosis Treatment by region & country, by Type, and by Application. The Kidney Fibrosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Treatment. Market Segmentation
Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Kidney Fibrosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Revenue of Kidney Fibrosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Revenue of Kidney Fibrosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion.
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
English
Simon Lee
English
Hitesh
Chinese
Damon
Japanese
Tang Xin
Korean
Sung-Bin Yoon
Competition
Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.
Industry Analysis
Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.
Market Size
Capacity, production, sales, revenue, price, cost etc.
Customized Information
We can offer customized survey and information to meet ourclient's need.
Fastest report delivery service
More than 17 years of vast experience
Operation for 24 * 7 & 365 days
In-depth and comprehensive analysis
Professional and timely after-sales service
Owns large database
Add to Cart
Buy Now